July
September 25

Aryavart Journal of Multidisciplinary Research
(NATIONAL PEER REVIEWED E-RESEARCH JOURNAL)
E-ISSN 3107-6009

Vol - 1
Issue - 3

Explorationof Advent tools in Diagnosis and Management of Anti-hypertensive Drugs: A Review

Sujata[1], Neha[2], Urvashi[3], Madhu[4], Anand Chaurasia*
Sujata Kushwaha
Department of Pharmacy
Aryavart University, Sehore (M.P.)

ABSTRACT

Drugs are medications used to lower high blood pressure (hypertension) and reduce the risk of complications such as stroke, heart attack, heart failure, and kidney disease. They act on different physiological Antihypertensive pathways to reduce vascular resistance, blood volume, or cardiac output.Hypertension remains a leading global risk factor forcardiovascular morbidity and mortality. Limitations of current antihypertensive therapy include suboptimal adherence, systemic side effects, and variability in pharmacokinetics and pharmacodynamics. Combining advances in targeted drug-delivery systems with artificial intelligence (AI) holds promise to personalize and optimize antihypertensive therapy.

KEYWORDS

Hypertension, Antihypertensive drugs, Targeted drug delivery, Nanocarriers, Artificial intelligence, Machine learning, Personalized medicine.

1. INTRODUCTION

Hypertension affects a large proportion of the adult population worldwide and is a primary driver of heart disease, stroke and renal failure. Standard antihypertensive regimens rely on oral daily dosing or transdermal patches for some agents; however, many patients experience inadequate control or adverse effects due to systemic exposure and inter-individual variability. Targeted drug delivery aims to concentrate therapeutic action where needed, reduce systemic exposure, and provide controlled release. Artificial intelligence (AI) offers tools to accelerate the design of delivery vehicles, predict individual responses, and control delivery in closed-loopsystems. This review details how AI can be integrated with novel targeted delivery approaches for antihypertensive therapy.



Aryavart Journal of Multidisciplinary Research
(NATIONAL PEER REVIEWED E-RESEARCH JOURNAL)
E-ISSN 3107-6009

FIGUER NO .1 DETECTION OF HYPERTENSION

HYPERTENSIVE AGENTS		
No.	**Class**	**Drugs**
1	ACE inhibitors (Angiotensin converting enzyme inhibitors)	Enalapril, Lisinopril, Ramipril, Captopril
2	ARBs (Angiotensin receptor blockers)	Telmisartan, Olmesartan, Losartan, Candesartan, Valsartan
3	Calcium channel blockers	Amlodipine, Felodipine, Nimodipine, Nifedipine, Isradipine, Verapamil, Diltiazem
4	Beta blockers	Atenolol, Metoprolol, Bisoprolol, Labetolol, Propranolol,
5	Diuretics	Hydrochlorthiazide, Chlorthiazide, Chlorthalidone, Spironolactone, Furosemide
6	Direct Vasodilators	Hydralazine, Minoxidil, Sodium Nitropruside, Diazoxide
7	Alpha blockers	Terazosin, Doxazosin, Prazosin
8	Central Alpha 2 Agonists	Clonidine, Methyldopa

FIGUER NO 2 HYPERTENSIVE AGENTS

1. Diuretics (reduce blood volume)

- **Thiazide diuretics**: Hydrochlorothiazide, Chlorthalidone, Indapamide
- **Loop diuretics**: Furosemide, Bumetanide, Torsemide.



Furosemide

- **Potassium-sparing diuretics**: Spironolactone, Eplerenone, Amiloride

2. Sympatholytic (Anti-Adrenergic) Drugs

Aryavart Journal of Multidisciplinary Research
(NATIONAL PEER REVIEWED E-RESEARCH JOURNAL)
E-ISSN 3107-6009

- **Beta-blockers**: Propranolol, Atenolol, Metoprolol, Carvedilol.



Beta-blockers

- **Alpha-1 blockers**: Prazosin, Doxazosin, Terazosin
- **Central alpha-2 agonists**: Clonidine, Methyldopa
- **Adrenergic neuron blockers**: Reserpine

3. Vasodilators (directly relax vascular smooth muscle)

- **Direct vasodilators**: Hydralazine, Minoxidil.



Hydralazine

- **Sodium nitroprusside** (used in hypertensive emergencies)

4. Calcium Channel Blockers (CCBs)

- **Dihydropyridines**: Amlodipine, Nifedipine, Felodipine
- **Non-dihydropyridines**: Verapamil, Diltiazem.



Verapamil

5. Drugs Acting on the Renin–Angiotensin–Aldosterone System (RAAS)

- **ACE inhibitors**: Captopril, Enalapril, Lisinopril, Ramipril.

Aryavart Journal of Multidisciplinary Research
(NATIONAL PEER REVIEWED E-RESEARCH JOURNAL)
E-ISSN 3107-6009



Captorpril

- **Angiotensin II receptor blockers (ARBs)**: Losartan, Valsartan, Telmisartan
- **Renin inhibitors**: Aliskiren
- **Aldosterone antagonists**: Spironolactone, Eplerenone



Valsartan, an ARB

6. Other Agents

- **Endothelin receptor antagonists**: Bosentan.



Bosentan

- **Vasopeptidase inhibitors** (experimental/limited use)

2. METHODS

1. Search strategy (suggested reproducible approach)

To reproduce a literature review, search these terms (combine using AND/OR):

a) Hypertension or antihypertensive and targeted drug delivery or nanoparticle or liposome or microsphere or implantable.

b) Closed-loop or smart pump or wearable drug delivery and blood pressure or hypertension.

Aryavart Journal of Multidisciplinary Research
(NATIONAL PEER REVIEWED E-RESEARCH JOURNAL)
E-ISSN 3107-6009

2. Background — targeted delivery and antihypertensives

a). Rationale for targeted delivery in hypertension

- Reduce systemic side effects (e.g., orthostatic hypotension, renal effects).
- Improve therapeutic index by delivering drugs to vascular beds, kidneys, or sympathetic ganglia.
- Improve adherence via long-acting depots or implantable.

b). Common antihypertensives that are candidates for targeted delivery

- ACE inhibitors, ARBs: reduce systemic RAAS activity — could benefit from kidney-targeted delivery.
- Calcium channel blockers: vascular smooth muscle targeting may enhance local vasodilation.
- Beta-blockers: targeted cardiac delivery potentially lowers systemic bradycardia.
- Diuretics: renal targeting to increase natriuretic effects with less systemic electrolyte changes.

3. Targeted delivery platforms relevant to antihypertensives

a). Nanocarriers (liposomes, polymeric nanoparticles, dendrimers)

- Advantages: modifiable surface ligands, controlled release, renal or vascular targeting.
- Challenges: clearance by RES, scale-up, long-term safety.

b). Ligand-mediated targeting

- Use ligands or antibodies targeting endothelial markers, renal tubular receptors, or organ-specific biomarkers.

c). Stimuli-responsive systems

- pH, enzyme, redox or shear-stress responsive carriers that release drug in disease microenvironments (e.g., high shear in stenotic vessels).

d). Depot/implantable systems and microneedles

- Long-acting depots (biodegradable microspheres) or minimally invasive implantables for weeks-to-months dosing; microneedle patches for transdermal sustained release.

e). Wearables and closed-loop devices

- Wearables that measure BP and control actuated pumps/patches to titrate doses in near real-time.

4. AI methods applied to drug delivery

a). Data-driven design and materials discovery

- ML for predicting nanoparticle stability, drug loading, release profiles from formulation parameters.
- Generative models (e.g., variational autoencoders, GANs) to propose novel polymer chemistries or ligand sequences.

b). Pharmacokinetic/pharmacodynamic (PK/PD) modeling

Aryavart Journal of Multidisciplinary Research
(NATIONAL PEER REVIEWED E-RESEARCH JOURNAL)
E-ISSN 3107-6009

- ML and hybrid models to predict individual PK/PD using multimodal data (genetics, biomarkers, comorbidities).
- Physiologically based pharmacokinetic (PBPK) models enhanced by ML for parameter estimation.

c). Reinforcement learning and control systems

- RL for dose scheduling and closed-loop control based on continuous BP measurements to optimize therapeutic effect and minimize side effects.

d). Imaging and targeting.

- Deep learning for image segmentation and biomarker quantification (e.g., identify vascular plaques or renal regions) to guide targeted delivery.

e). Explainability & uncertainty quantification

- Essential for clinical adoption — use interpretable models, SHAP/LIME explanations, and Bayesian uncertainty estimates.

5. Application of AI + targeted delivery to antihypertensives — examples and mechanisms

a). Design examples (preclinical)

- ML models predicting how polymer composition and particle size affect release kinetics tailored to a specific antihypertensive's half-life.
- AI optimization of ligand density for endothelial targeting to improve nanoparticle retention in arterial walls.

b). Personalized dosing

- Combining wearable BP data, electronic health records and PK/PD predictions to recommend individualized release rates for an implantable depot.

c). Closed-loop systems

- Wearable BP monitor → AI controller predicts next dosing action → microneedle patch actuated to release a bolus or increase baseline release.

d). Safety monitoring and adverse event prediction

- ML models to flag patients at higher risk of hypotension or electrolyte imbalance following targeted renal delivery.

3. APPLICATIONS IN DIAGNOSIS

✓ **Wearable Technology:**

AI can estimate blood pressure (BP) by analyzing signals from smartwatches and smartphones, providing continuous, real-time data that aids in early detection and intervention.

✓ **Diagnostic Imaging:**

Machine learning (ML) algorithms can analyze medical images like retinal scans and vascular images to find early signs of hypertension-related organ damage.

✓ **Physiological Signals:**

Aryavart Journal of Multidisciplinary Research
(NATIONAL PEER REVIEWED E-RESEARCH JOURNAL)
E-ISSN 3107-6009

AI can interpret signals from devices like electrocardiograms (ECGs) to detect early signs of hypertension and associated conditions

✓ **Multi-Modal Data Integration:**

AI can combine clinical data, physiological signals, and medical images for a more comprehensive understanding of hypertension and its underlying factors.

4. APPLICATIONS IN MANAGEMENT

❖ **Risk Stratification:**

AI helps identify at-risk patients by analyzing diverse data streams, enabling proactive intervention.

❖ **Personalized Treatment:**

AI can predict individual patient responses to different medications, guiding the selection of the most appropriate and effective therapies.(14)

❖ **Personalized Treatment:**

AI can predict individual patient responses to different medications, guiding the selection of the most appropriate and effective therapies

❖ **Personalized Treatment:**

AI can predict individual patient responses to different medications, guiding the selection of the most appropriate and effective therapies.(15)

5. CHALLENGES AND FUTURE DIRECTIONS

- **Data Privacy and Ethics:** Safeguarding patient data and addressing potential biases in AI algorithms are critical.
- **Integration into Practice:** Widespread adoption requires integration into existing clinical workflows and the development of robust ethical framework.(16)
- **Model Validation:** AI-driven hypertension models need to be tested and validated on diverse patient populations to ensure their effectiveness across different groups. (17)

6. RESULTS OF EXISTING STUDIES (SUMMARY)

Provide a table summarizing representative studies (replace bracketed items with real citations):

Study (Year)	Platform	Antihypertensive	AI method	Model/Stage	Key findings
[Ref A]	Polymeric nanoparticle	Lisinopril (example)	ML optimization	In vitro/rodent	Improved targeted accumulation in kidney; reduced systemic exposure
[Ref B]	Microneedle patch + pump	Beta-blocker	RL controller	Preclinical	Closed-loop control reduced BP variability

Aryavart Journal of Multidisciplinary Research
(NATIONAL PEER REVIEWED E-RESEARCH JOURNAL)
E-ISSN 3107-6009

Study (Year)	Platform	Antihypertensive	AI method	Model/Stage	Key findings
					in animal model
[RefC]	Liposome + ligand	CCB	Generative design	In vitro	Increased vascular retention(18)

CONCLUSION

AI-driven targeted delivery has the potential to markedly improve antihypertensive therapy by enabling organ- or cell-specific delivery, personalized dosing, and closed-loop control. While promising technologies exist, dedicated antihypertensive translational studies, open data, robust AI validation, and clear regulatory strategies are required before widespread clinical adoption.(19)Integrating robust AI models with advanced targeted delivery systems could transform hypertension management by enabling precision dosing, reducing side effects, and improving adherence. Focused translational studies, standardized datasets, and regulatory frameworks are urgently needed. Nevertheless, with the innovative development of AI technology, AI has the potential to overcome the stagnation in hypertension and all aspects of hypertension clinical practice, including BP measurement, diagnosis, prognostication, and management. Collaboration with medical professionals, particularly in the field of hypertension research, is crucial during the development and validation process of the AI model to ensure clinical relevance.

REFERENCES

1. Sabatino J, Avesani M, Sirico D, Reffo E, Castaldi B, Bassareo P, et al. Systemic hypertension in adults with congenital heart diseases. Int J CardiolCongenit Heart Dis. 2023.
2. Sun J, Qiao Y, Zhao M, Magnussen CG, Xi B. Global, regional, and national burden of cardiovascular diseases in youths and young adults aged 15–39 years in 204 countries/territories, 1990–2019: a systematic analysis of Global Burden of Disease Study 2019. BMC Med. 2023.
3. Barrett J.S., Oskoui S.E., Russell S., Borens A. Digital Research Environment(DRE)-enabled Artificial Intelligence (AI) to facilitate early stage drug development. Front. Pharmacol. 2023.
4. Chakravarty K., Antontsev V.G., Khotimchenko M., Gupta N., Jagarapu A., Bundey Y., Hou H., Maharao N., Varshney J. Accelerated Repurposing and Drug Development of Pulmonary Hypertension Therapies for COVID-19 Treatment Using an AI-Integrated Biosimulation Platform. Molecules. 2021.
5. kin PM et al (2022) Electrocardiographic strain pattern and prediction of cardiovascular morbidity and mortality in hypertensive patients. Hypertension.

6. Reeve E, Jordan V, Thompson W, Sawan M, Todd A, Gammie TM, et al. (June 2020). "Withdrawal of antihypertensive drugs in older people". *The Cochrane Database of Systematic Reviews*. 2020.
7. Mura S, Manconi M, Fadda AM, Sala MC, Perricci J, Pini E, Sinico C. 2020. Penetration enhancer-containing vesicles (PEVs) as carriers for cutaneous delivery of minoxidil: in vitro evaluation of drug permeation by infrared spectroscopy. Pharm Dev Technol.
8. Maase M, Rygula A, Pacia MZ, Proniewski B, Mateuszuk L, Sternak M, et al. Combined Raman- and AFM-based detection of biochemical and nanomechanical features of endothelial dysfunction in aorta isolated from ApoE/LDLR−/− mice. Nanomedicine. 2019.
9. Bartosch AMW, Mathews R, Tarbell JM. Endothelial glycocalyx-mediated nitric oxide production in response to selective AFM pulling. Biophys J. 2017.
10. Tran N, Garcia T, Aniqa M, Ali S, Ally A, Nauli SM. Endothelial Nitric Oxide Synthase (eNOS) and the cardiovascular system: in physiology and in disease states. Am J Biomed Sci Res. 2022.
11. Ding J, Yu M, Jiang J, Luo Y, Zhang Q, Wang S, et al. Angiotensin II decreases endothelial nitric oxide synthase phosphorylation via AT1R Nox/ROS/PP2A pathway. Front Physiol. 2020.
12. Brubaker SW, Brewer SM, Massis LM, Napier BA, Monack DM. A rapid caspase-11 response induced by IFNγ priming is independent of guanylate binding proteins. iScience. 2020,
13. Orejudo M, Rodrigues-Diez RR, Rodrigues-Diez R, Garcia-Redondo A, Santos-Sánchez L, Rández-Garbayo J, et al. Interleukin 17A participates in renal inflammation associated to experimental and human hypertension. Front Pharmacol. 2019.
14. Percha B, Baskerville EB, Johnson M, Dudley JT, Zimmerman N. Designing robust N-of-1 studies for precision medicine: simulation study and design recommendations. J Med Internet Res 2019.
15. Ihm S-H, Park J-H, Kim JY, Kim J-H, Kim K-I, Lee EM, Lee H-Y, Park S, Shin J, Kim C-H. Home blood pressure monitoring: a position statement from the Korean Society of Hypertension Home blood pressure forum. Clin Hypertens. 2022.
16. Zhou B, Perel P, Mensah GA, Ezzati M. Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol. 2021.
17. Kim HL, Lee EM, Ahn SY, Kim KI, Kim HC, Kim JH, Lee HY, Lee JH, Park JM, Cho EJ, Park S, Shin J, Kim YK. The 2022 focused update of the 2018 Korean Hypertension Society Guidelines for the management of hypertension. Clin Hypertens. 2023.
18. Yusuf M, Atal I, Li J, Smith P, Ravaud P, Fergie M, Callaghan M, Selfe J. Reporting quality of studies using machine learning models for medical diagnosis: a systematic review. BMJ Open. 2020.

19. Kelly CJ, Karthikesalingam A, Suleyman M, Corrado G, King D. Key challenges for delivering clinical impact with artificial intelligence. BMC Med. 2019.
20. M. Simjanoska, S. Kochev, J. Tanevski, A.M. Bogdanova, G. Papa, T. Eftimov Multi-level information fusion for learning a blood pressure predictive model using sensor data Inf. Fusion, 58 (2020), pp. 24-39.
21. GBD 2021 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2021: A systematic analysis for the Global Burden of Disease Study 2019. *Lancet* **2020**, *396*, 1223–1249.
22. Naik, A.; Nalepa, J.; Wijata, A.M.; Mahon, J.; Mistry, D.; Knowles, A.T.; Dawson, E.A.; Lip, G.Y.H.; Olier, I.; Ortega-Martorell, S. Artificial intelligence and digital twins for the personalised prediction of hypertension risk. *Comput. Biol. Med.* 2025.